Fig. 1 · Structure

Documents & Downloads

Apatinib (YN968D1)

Cat. No. A11407 CAS 811803-05-1

VEGFR inhibitor

Apatinib (YN968D1) is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR) that inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.

In Stock

Publications for Apatinib

2 publications citing this product

  1. Wonjin Park, .et al. , Biomed Pharmacother, 2021, Feb;134:111110 PMID: 33338749
  2. Majid Momeny, .et al. , Sci Rep, 2017, 7: 45954 PMID: 28383032

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Apatinib mesylate (YN968D1) inhibited VEGFR-2 kinase with a reported IC50 of 0.001 μM in an ELISA panel. Ret, c-kit and c-src were also inhibited, so selectivity is relative to the tested panel. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
VEGFR2 IC50 1nM
RET IC50 13nM
c-Kit IC50 429nM
c-Src IC50 530nM
PDGFRα IC50 >1μM
EGFR IC50 >10μM
HER2 IC50 >10μM
FGFR1 IC50 >10μM

8 targets · Scroll to view more

Apatinib (YN968D1) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Apatinib (YN968D1) from 2 published references. In vitro models include primary human umbilical vein endothelial cells (HUVEC).

Apatinib (YN968D1) In Vitro Studies

In HUVEC, 72 h proliferation IC50 values were 0.17 μM with VEGF and 23.4 μM with FBS stimulation, demonstrating strong dependence on assay context. [1]

In primary epithelioid peritoneal mesothelioma cells, apatinib did not produce detectable apoptotic nuclear changes or increased caspase activity after 24 h under the tested conditions. This negative result is model- and endpoint-specific. [2]

Cell-free kinase inhibition panel

Biochemical assay · Isolated tyrosine kinases; sunitinib comparator [1]

VEGFR-2 inhibition was strongest among the tested kinases; selectivity was relative, not absolute.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGFR-2 kinase activityIC50 0.001 μM (YN968D1); 0.005 μM (sunitinib)[1]
Other kinase activitiesIC50 Ret 0.013 μM; c-kit 0.429 μM; c-src 0.53 μM; PDGFRα >1 μM; EGFR >10 μM; Her-2 >10 μM; FGFR1 >10 μM[1]

Literature-Reported Treatment Conditions

Method
ELISA kinase assay; Logit IC50 from three independent experiments
Reported limits
ATP concentration and exposure duration are not specified in the retrieved assay paragraph; no kinetic binding claim is made.
Methods and source locations

Compound reported in the paper: Apatinib mesylate; Compound label in the paper: YN968D1

Published material and model only; no verification of the A11407 lot or salt conversion.

Table 3; Methods: Enzyme-linked immunosorbent assay; Results: Inhibition of tyrosine kinase activities

VEGFR-2 kinase activity: ELISA; three independent experiments — Table 3; Enzyme-linked immunosorbent assay

Other kinase activities: ELISA — Table 3

Stimulus-dependent endothelial proliferation

Cell-based study · Primary human umbilical vein endothelial cells (HUVEC) [1]

The proliferation endpoint was more sensitive under VEGF stimulation than under FBS stimulation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HUVEC proliferation under the indicated stimulusIC50 VEGF: 0.17 μM; FBS: 23.4 μM (YN968D1). Sunitinib: 0.034 μM and 7.4 μM, respectively.[1]

Literature-Reported Treatment Conditions

Exposure duration
72 h drug exposure
Method
Sulforhodamine B proliferation assay; vehicle control and sunitinib comparator
Vehicle
DMSO stock; final percentage not specified
Co-treatment
20 ng/mL VEGF or 20% FBS as stimulus
Reported limits
Exact drug dilution series and replicate n for this panel are not specified; IC50 values are reported in Results.
Methods and source locations

Compound reported in the paper: Apatinib mesylate; Compound label in the paper: YN968D1

Published material and model only; no verification of the A11407 lot or salt conversion.

Figure 3A and caption; Methods: Cell proliferation assays; Results: Inhibition of proliferation, migration and tube formation of HUVEC

HUVEC proliferation under the indicated stimulus: Sulforhodamine B, 72 h — Results: Inhibition of proliferation, migration and tube formation; Figure 3A; Cell proliferation assays

No detected apoptosis increase in primary mesothelioma cells

Cell-based study · Primary epithelioid malignant peritoneal mesothelioma cells derived from one patient via xenograft [2]

DAPI morphology and caspase assays did not detect an apoptosis increase under the tested conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptotic morphology and caspase activityReported negative result No apoptotic features versus blank control by DAPI; no significant caspase activity difference versus control (P>0.05).[2]

Literature-Reported Treatment Conditions

Treatment concentration
DAPI: 50 μM; caspase: 1, 2, 4, 8, 16, 32 and 64 μM
Exposure duration
24 h
Method
DAPI nuclear morphology; Caspase-Glo 3/7 luminescence
Vehicle
DMSO stock; final fraction not specified
Reported limits
Figure 3D labels blank, negative and positive controls, but control identities are not specified in the apoptosis methods. Exact assay-specific replicate n is not given; general Methods states at least three repeats.
Methods and source locations

Compound reported in the paper: Apatinib mesylate; Compound label in the paper: apatinib

Published material and model only; no verification of the A11407 lot or salt conversion.

Methods: Apoptosis Assays; Results: Apatinib Does Not Induce Apoptosis of MPM Cells; Figure 3C–D

Apoptotic morphology and caspase activity: DAPI and Caspase-Glo 3/7; Methods calls the latter a caspase-3 assay — Figure 3C–D; Results: Apatinib Does Not Induce Apoptosis of MPM Cells

Apatinib (YN968D1) In Vivo Studies

In a single-donor mesothelioma PDX, daily oral apatinib for two weeks reduced peritoneal tumor-burden scores versus both controls. Body weight was unaffected, but focal liver and cardiac lymphoid infiltrations were observed. Survival was not assessed, and tumor VEGFR-2 positivity did not change significantly. [2]

Tumor-burden reduction and tolerability in an MPM PDX

Animal study · BALB/c nu/nu mice with intraperitoneal epithelioid MPM PDX from one patient; randomized three groups, n=6 each [2]

ePCI decreased relative to both controls. Body weight was unaffected, but focal lymphoid infiltration occurred in liver and cardiac muscle. Mesenteric invasion persisted in 5/6 mice in each group (Table 2).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Experimental peritoneal cancer index (0–13)mean ± SD Blank: 9.8 ± 0.9; solvent: 10.3 ± 0.9; apatinib: 7.3 ± 1.6. P = 0.003 overall; blank vs apatinib P = 0.008; solvent vs apatinib P = 0.001; blank vs solvent P = 0.394.[2]
Body weight, organ histology and tumor VEGFR-2 positivityReported outcomes No body-weight effect; focal lymphoid infiltration in liver (16.7%) and cardiac muscle (16.7%) in apatinib group. VEGFR-2 positivity: 61.4 ± 8.7% vs 65.3 ± 9.9% control; P = 0.119.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Blank controlNo interventionePCI 9.8 ± 0.9.[2]
Solvent control
24 μg/g/day 0.5% CMC (as written)
Blank controlePCI 10.3 ± 0.9.[2]
Apatinib
100 μg/g/day
Blank and solvent groupsePCI 7.3 ± 1.6; lower than both controls. Focal liver and cardiac lymphoid infiltrations each reported in 16.7%.[2]
Blank control
Model: Single-donor epithelioid MPM intraperitoneal PDX in BALB/c nu/nu mice; n=6/group
Reported limits: Sex is not specified in the animal methods. No survival endpoint.
Solvent control
Model: Single-donor epithelioid MPM intraperitoneal PDX in BALB/c nu/nu mice; n=6/group
Frequency: Daily
Treatment course: 2 weeks
Vehicle: 0.5% CMC
Reported limits: Sex is not specified in the animal methods. No survival endpoint.
Apatinib
Model: Single-donor epithelioid MPM intraperitoneal PDX in BALB/c nu/nu mice; n=6/group
Route: Intragastric gavage
Frequency: Daily
Treatment course: 2 weeks
Vehicle: 0.5% CMC
Reported limits: Sex is not specified in the animal methods. No survival endpoint.
Methods and source locations

Compound reported in the paper: Apatinib mesylate; Compound label in the paper: apatinib

Published material and model only; no verification of the A11407 lot or salt conversion.

Figure 6A–B,E–F; Table 2; Methods: Apatinib to Treat MPM PDX Model; Statistical Analysis; Results: Efficacy and Toxicity of Apatinib on MPM PDX Model; Figure 6; Table 2; Table 2

Experimental peritoneal cancer index (0–13): Macroscopic lesion-size/ascites scoring; n=6/group; Methods describes ANOVA and Student’s t-test — Figure 6B; Results: Apatinib Decreases ePCI Score; Statistical Analysis

Body weight, organ histology and tumor VEGFR-2 positivity: Weight monitoring, HE histology and IHC; mean ± SD for positivity — Figure 6A,E–F; Results: Organ Toxicity and Apatinib Decreases ePCI Score

Blank control · Methods: Apatinib to Treat MPM PDX Model; Statistical Analysis; Results: Efficacy and Toxicity of Apatinib on MPM PDX Model; Figure 6; Table 2

Solvent control · Methods: Apatinib to Treat MPM PDX Model; Statistical Analysis; Results: Efficacy and Toxicity of Apatinib on MPM PDX Model; Figure 6; Table 2

Apatinib · Methods: Apatinib to Treat MPM PDX Model; Statistical Analysis; Results: Efficacy and Toxicity of Apatinib on MPM PDX Model; Figure 6; Table 2

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 811803-05-1
Applications VEGFR inhibitor
Formula C25H27N5O4S
Molecular Weight 493.6
Synonyms YN968D1
SMILES
CS(=O)(=O)O.C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 77 mg/mL (193.72 mM)
Water Insoluble
Ethanol 10 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Apatinib (YN968D1) Research References

  1. [1] Shu Tian, Haitian Quan, Chengying Xie, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo Cancer Science (2011). PMID: 21443688 DOI: 10.1111/j.1349-7006.2011.01939.x Source material
  2. [2] Zhi-Ran Yang, Zhi-Gao Chen, Xue-Mei Du, et al. Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo Frontiers in Oncology (2020). PMID: 33365269 DOI: 10.3389/fonc.2020.585079 Source material

Publications

2 publications citing this product

  1. Wonjin Park, .et al. , Biomed Pharmacother, 2021, Feb;134:111110 PMID: 33338749
  2. Majid Momeny, .et al. , Sci Rep, 2017, 7: 45954 PMID: 28383032

Added to your cart

View Cart Checkout
Loading...